Skip to main content
. 2022 Jul 22;23(15):8083. doi: 10.3390/ijms23158083

Figure 1.

Figure 1

Metformin improved the efficacy of sorafenib in HCC cells. (A) Line graph represents the tumor progression curve of HepG2 -derived tumors treated with vehicle and metformin (200 mM). (B) Cell cycle analysis of HepG2 and Huh7 cells treated with 10 µM sorafenib (S10), 5 µM sorafenib (S5), 5 mM metformin (M5), and the combination of 5 µM sorafenib and 5 mM metformin (S5 + M5). (C–F) HepG2 and Huh7 were treated with 10 µM, 5 µM, and 2.5 µM sorafenib (S10, S5, S2.5) and/or 5 mM metformin (M5) either alone or in combination for 12 and 24 h, respectively. (C,D) Trypan blue dye exclusion assay was performed to assess cell survival. Graphs represent the number of viable cells. (E,F) XTT assay was performed to assess cell viability. Graphs represent the optical density of absorbance at 450/690 of the samples. * p < 0.05.